Boost treatment before surgery for luminal B breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a “boost” treatment given before surgery along with standard chemotherapy for luminal B–type breast cancer. It may help improve outcomes by strengthening treatment before the tumor is removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have luminal B–like breast cancer
- Your tumor is early stage (cT1–2)
- Your doctors have recommended chemotherapy before surgery (neoadjuvant chemotherapy)
- You are not pregnant
- You are not breastfeeding
- You can take part in follow-up visits after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a single, very targeted dose of radiation right after surgery for early-stage breast cancer. It is for women age 40+ with small, low-risk tumors (Luminal A or B) that have been fully removed and have not spread to lymph nodes.
This trial tests adding radiation therapy to chemotherapy before surgery for people with locally advanced breast cancer that did not shrink enough with chemo alone. It may help improve outcomes for those with luminal (HER2-negative) or triple-negative types.
This trial tests a new combination of treatments given before surgery for hormone receptor positive, HER2 negative breast cancer. It uses stereotactic body radiation therapy (SBRT), chemotherapy, and an investigational drug called AK112 to shrink tumors and make surgery easier.
This trial tests a short, highly targeted radiation plan given in five sessions after lumpectomy for early-stage breast cancer. It may help treat the remaining breast area while aiming to limit exposure to healthy tissue.
This trial studies whether a specific radiation approach after lumpectomy can be helpful for certain people with early breast cancer that did not spread to lymph nodes at diagnosis. It focuses on people who finish neoadjuvant (before-surgery) treatment and reach a full response on final pathology.
This trial tests a treatment given before breast surgery to shrink breast cancer and improve outcomes based on your tumor type. Your eligibility depends on tumor size/stage, hormone and HER2 markers, and overall health checks.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.